Expression and function of peroxisome proliferator-activated receptor-γ in mesangial cells

Hypertension

Volumn 37, Issue 2 II, 2001, Pages 722-727

  Nicholas, Susanne B ^a   Kawano, Yasuko ^b   Wakino, Shu ^a   Collins, Alan R ^a   Hsueh, Willa A ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b NAGASAKI UNIVERSITY HOSPITAL   (Japan)

Author keywords

Albuminuria; Diabetes mellitus; Insulin; Kidney; Mesangium

Indexed keywords

ALBUMIN; BROXURIDINE; CREATININE; GLUCOSE; INSULIN; MATRIX METALLOPROTEINASE INHIBITOR; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PLASMINOGEN ACTIVATOR INHIBITOR 1; PLATELET DERIVED GROWTH FACTOR; STREPTOZOCIN; TROGLITAZONE;

ANIMAL CELL; ANIMAL MODEL; ANIMAL TISSUE; CONFERENCE PAPER; CONTROLLED STUDY; DIABETIC NEPHROPATHY; DRUG MECHANISM; DRUG RECEPTOR BINDING; GLUCOSE TRANSPORT SYSTEM; INSULIN METABOLISM; MESANGIUM CELL; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RAT;

EID: 0035098304     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.hyp.37.2.722     Document Type: Conference Paper

References (41)

1. Control of the peroxisomal b-oxidation pathway by a novel family of nuclear hormone receptors
2. Activation of a member of the steroid hormone receptor superfamily by peroxisome proliferators
3. Structural organization of mouse peroxisome proliferator-activated receptor γ (mPPARγ) gene: Alternative promoter use and different splicing yield two mPPARγ isoforms
4. The structure-activity relationship between peroxisome proliferator-activated receptor gamma agonism and the antihyperglycemic activity of thiazolidinediones
5. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines
6. Peroxisome proliferator-activated receptor and retinoid X receptor ligands inhibit monocyte chemotactic protein-1-directed migration of monocytes
7. Expression and function of PPARγ in rat and human vascular smooth muscle cells
8. The peroxisome proliferator-activated-gamma is a negative regulator of macrophage activation
9. Thiazolidinediones
10. Troglitazone lowers blood pressure and enhances insulin sensitivity in Watanabe heritable hyperlipidemic rabbits
11. The thiazolidinedione rosiglitazone (BRL-49653) lowers blood pressure and protects against impairment of endothelial function in Zucker fatty rats
12. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy
13. Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats
14. Peroxisome proliferator-activated receptor-γ agonist, rosiglitazone, protects against nephropathy and pancreatic islet abnormalities in Zucker fatty rats
15. Isolated glomeruli and cultured mesangial cells as in vitro models to study immunosuppressive agents
16. Analysis of a tissue-specific enhancer: ARF6 regulates adipogenic gene expression
17. Uber den Niederschiag, welchen Picrinsaure in normalen Hamerzeugt und uber eine neue Reaction des Kreatinins
18. Peroxisome proliferator-activated receptor gamma (PPARgamma 1) expresses in rat mesangial cells and PPARgamma agonists modulate its differentiation
19. Two classes of PDGF receptor recognize different isoforms of PDGF
20. Isolation of a novel receptor cDNA establishes the existence of two PDGF receptor genes
21. High-level expression of RXRα and the presence of endogenous ligands contribute to expression of a peroxisome proliferator-activated receptor-responsive gene in hepatoma cells
22. Thiazolidinedione compounds ameliorate glomerular dysfunction independent of their insulin-sensitizing action in diabetic rats
23. Thiazolidinediones down-regulate plasminogen activator inhibitor type 1 expression in human vascular endothelial cells: A possible role for PPARgamma in endothelial function
24. Measurement of renin and interpretation of plasma renin activity
25. Cellular events in the evolution of experimental diabetic nephropathy
26. Ligands for peroxisome proliferator-activated receptor gamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice
27. Effects of ligand activation of peroxisome proliferator-activated receptor gamma in human prostate cancer
28. Peroxisome proliferator-activated receptor-gamma ligands inhibit choroidal neovascularization
29. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1→S transition in reticular smooth muscle cells
30. Insulin and angiotensin II are additive in stimulating TGF-B1 and matrix mRNA in mesangial cells
31. Glomerular volume expansion and mesangial cell mechanical strain: Mediators of glomerular pressure injury
32. Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-B expression in rat glomerular mesangial cells
33. High glucose activates protein kinase C and stimulates fibronectin gene expression by enhancing a cAMP response element
34. Dual effects of angiotensin II on the plasminogen/plasmin system in rat mesangial cells
35. Modulation of plasminogen activator inhibitor-1 in vivo: A new mechanism for the anti-fibrotic effect of renin-angiotensin inhibitor
36. ECM degradation by cultured human mesangial cells is mediated by a PA/plasmin/MMP-2 cascade
37. Bleomycin-induced pulmonary fibrosis in transgenic mice that either lack or overexpress the murine plasminogen activator inhibitor-1 gene
38. Troglitazone improves defects in insulin action, insulin secretion, ovarian steroidogenesis, and fibrinolysis in women with polycystic ovary syndrome
39. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes and in lean and obese normal subjects
40. Inhibition of mesangial cell nitric oxide in MRL/Ipr mice by prostaglandin J2 and proliferator activation receptor-gamma agonists
41. Troglitazone inhibits vascular smooth muscle cell growth and intimal hyperplasia